Clinical trials: Advanced Head and Neck Squamous Cell Carcinoma
Oesophageal Squamous Cell Carcinoma, Gastric Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years…
- Conditions
- Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT05104567
- Testing
- THOR-707, Pembrolizumab, Cetuximab
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Solid Tumor Cancer, Adult Refractory Cancer
Study of GV20-0251 in Participants With Solid Tumor Malignancies
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT07070518
- Testing
- GV20-0251
- Where
- 3 sites in China
- Volunteers
- 350 people
- Sponsor
- GV20 Therapeutics
Solid Tumors
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in participant with…
- Trial name
- NCT03347123
- Testing
- Epacadostat, Nivolumab, Ipilimumab
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Incyte Corporation
Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
This is a Phase 2, multicenter, open-label, 2-cohort (Locoregionally Advanced Cohort or Recurrent/Metastatic Cohort) study evaluating RP3 in combination with concurrent chemoradiation therapy (CCRT) followed by nivolumab (for the…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05743270
- Testing
- RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel
- Where
- 34 sites in United States, Czechia and 6 more
- Sponsor
- Replimune, Inc.
Locally Advanced Head and Neck Squamous Cell Carcinoma
the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer
This study is to observe and compare the effect of docetaxel plus lobaplatin induction chemotherapy combined with lopoplatin chemoradiotherapy and TPF induction chemotherapy combined with cisplatin chemoradiotherapy on dendritic…
- Trial name
- NCT03196869
- Testing
- Chrono-chemotherapy, Routine intravenous drip, induction Chrono-chemotherapy
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Guiyang Medical University
Squamous Cell Carcinoma of the Head and Neck, Melanoma
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT03894618
- Testing
- SL-279252
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 49 people
- Sponsor
- Shattuck Labs, Inc.
Carcinoma, Squamous Cell
A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer
This study involves two phases. Phase I of this study is designed to find out the maximum dose of paclitaxel poliglumex which can be safely given to subjects when combined with cetuximab and radiotherapy in head and neck cancer.
- Trial name
- NCT00660218
- Testing
- paclitaxel poliglumex, cetuximab, radiation therapy (IMRT or 3D-CRT)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- State University of New York - Upstate Medical University
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
This is a phase I/II multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of investigational agents with pembrolizumab, plus chemotherapy or lenvatinib, for the treatment of participants with…
- Trial name
- NCT05342636
- Testing
- Pembrolizumab, Coformulation favezelimab/pembrolizumab, MK-4830
- Where
- 46 sites in Brazil, Chile and 11 more
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer
A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC
Colorectal cancer (CRC) is one of the most common human malignant tumors. The incidence and mortality of colorectal cancer in our country are on the rise.
- Trial name
- NCT03491709
- Testing
- anti-EGFR monoclonal antibody, Cetuximab injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Dragonboat Biopharmaceutical Company Limited
Esophageal Squamous Cell Carcinoma
Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to observe and evaluate the efficacy and safety of dalpiciclib combined with pyrotinib as second-line therapy in patients with advanced esophageal squamous cell carcinoma.
- Trial name
- NCT06684600
- Testing
- Dalpiciclib + Pyrotinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Peking University
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma
- Trial name
- NCT05585034
- Testing
- XmAb®808, Keytruda® (pembrolizumab)
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Xencor, Inc.
Head and Neck Cancer
Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck Cancer
The purpose of this study was to evaluate the tolerability and efficacy of a combination of weekly docetaxel, cisplatin, and S-1 (weekly TPS) as induction chemotherapy in patients with locally advanced head and neck squamous cell…
- Trial name
- TPSHNSCC (NCT01645748)
- Testing
- S-1
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Chonnam National University Hospital
Cervical Cancer, Head and Neck Squamous Cell Carcinoma
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 TCR-T cell for HPV18 positive advanced solid tumor.
- Conditions
- Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Cancer, Vagina Tumor
- Trial name
- NCT05787535
- Testing
- Fludarabine + Cyclophosphamide, HRYZ-T101 TCR-T Cell
- Where
- China
- Volunteers
- 17 people
- Sponsor
- HRYZ Biotech Co.
Cancer, Tumor, Solid
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805…
- Conditions
- Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer
- Trial name
- NCT05094804
- Testing
- OR2805, Cemiplimab, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 172 people
- Sponsor
- OncoResponse, Inc.
Esophageal Cancer
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
This trial is conducted in patients with unresectable locally advanced esophageal squamous cell carcinoma. The investigators plan to enroll 60 patients with unresectable locally advanced esophageal cancer in Tianjin cancer…
- Trial name
- NCT06452602
- Testing
- Induction immunochemotherapy followed by Adebrelimab plus concurrent chemoradiotherapy, Induction immunochemotherapy followed by concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Locally Advanced Head and Neck Squamous Cell Carcinoma
Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer
This clinical trial is Phase II trial for evaluating efficacy of induction chemotherapy using Genexol-PM + cisplatin for locally advanced head and neck cancer.
- Trial name
- NCT01689194
- Testing
- genexolPM + cisplatin
- Where
- 2 sites in South Korea
- Volunteers
- 53 people
- Sponsor
- Seoul National University Hospital
Carcinoma
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
The main purpose of this observational study with Docetaxel is to determine the number of treatment cycles and the quantity of Doce onkovis needed therefore under the special circumstance of ambulant chemotherapy.
- Trial name
- NCT01614002
- Where
- 23 sites in Germany
- Volunteers
- 371 people
- Sponsor
- Onkovis GmbH
Squamous Cell Carcinoma, Head and Neck Cancer
Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
Whether low-dose radiation in addition to Taxotere and Erbitux improves the response rate of patients with recurrent unresectable head and neck squamous cell carcinoma.
- Conditions
- Squamous Cell Carcinoma, Head and Neck Cancer, Recurrent Disease
- Trial name
- NCT01794845
- Testing
- Erbitux, Taxotere, Low Dose Fractionated Radiation Therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Miami
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid…
- Conditions
- Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT07503808
- Testing
- IDE034
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- IDEAYA Biosciences
Advanced Malignancy, Advanced Solid Tumors
Safety Study of AMG 228 to Treat Solid Tumors
The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology
- Trial name
- NCT02437916
- Testing
- AMG 228
- Where
- 7 sites in United States, Australia and 3 more
- Volunteers
- 30 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.